23.5 C
New York
Monday, June 8, 2026

Tag: vaccines

newssourceFORcompanyinformationcontent1marketreleases

Chromatography Resin Market worth $4.94 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 1, 2025 /PRNewswire/ -- The report "Chromatography Resin Market by Type (Natural, Synthetic, Inorganic Media), Technique ((Ion Exchange (Cation and Anion), Affinity...

New Force in Vaccine National Team: NHRI Spin-off ‘TaiU’ Completes US$2M Seed Round Led by MVL Seed Fund

TAIPEI, Aug. 1, 2025 /PRNewswire/ -- Taiwan Universe BioMedicine (TaiU), a startup spun off from the National Health Research Institutes (NHRI), today announced the completion...

Evidence review suggests COVID-19 vaccines safe for pregnant women and their babies

WILLOW GROVE, Pa., July 31, 2025 /PRNewswire/ -- Pregnant women are at increased risk of illness due to infection compared with other adults, so...

Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025

LEXINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2025 financial results prior to the market open on Tuesday, August 12, 2025.

Press release: Online availability of Sanofi’s half-year financial report for 2025


Online availability of Sanofi’s half-year financial report for 2025

Bavarian Nordic Announces Closing of Sale of Priority Review Voucher and Upgrades its 2025 Financial Guidance

COPENHAGEN, Denmark, July 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its Priority Review Voucher (PRV). Upon completion, the company received a cash consideration of USD 160 million.

Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range


Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range

Eviva Partners Launches New Think Tank, Exposes Attack on Aluminum-Containing Vaccines

NEW YORK, July 30, 2025 /PRNewswire/ -- Eviva Partners, a nonprofit organization dedicated to strengthening public understanding of medical evidence, is proud to announce...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

WuXi Biologics Singapore CRDMO Hub Advances with the Launch of Modular Drug Product Facility Fabrication

Innovative modular design will accelerate construction and manufacturing timelines, enabling rapid adaptation of manufacturing capacities across diverse product formats.Finished building will be one of...

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

WALTHAM, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria. C3G and primary IC-MPGN are rare kidney diseases, affecting 5,000 people in the United States.1

Vaccines: Mythology, Ideology, and Reality, New Book by John Leake and Peter A. McCullough

NEW YORK, July 28, 2025 /PRNewswire/ -- Vaccines: Mythology, Ideology, and Reality tells the story of immunizations and the celebrated men who developed it with...

Biologic Therapeutics Market to Hit $794.5 Billion by 2029

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsVaccines

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers